| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e6971d1c99044b82544f4c48de994d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_689d532e7f712c780cb4cec200f16fef |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2009-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e475b02a7d216295aeb66d6b19d167ba |
| publicationDate |
2009-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009140741-A1 |
| titleOfInvention |
Agents and methods for diagnosing the presence or risk of prostate cancer |
| abstract |
The present invention discloses methods and agents for diagnosing the presence or risk development of prostate cancer in a subject. More particularly, the present invention discloses the use of certain PCA3 polynucleotides as markers for prostate cancer including metastatic prostate cancer. The invention has practical use in early diagnosis of prostate cancer, and in enabling better treatment and management decisions to be made in clinically and sub-clinically affected subjects. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9994912-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3530751-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10260104-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10604812-B2 |
| priorityDate |
2008-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |